Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Johnson & Johnson Opens State-of-the-Art Science and Technology Campus in San Francisco Bay Area
Johnson & Johnson (NYSE: JNJ) (the Company) today opened its San Francisco Bay Campus, a […]
CytoReason Announces Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development
CytoReason today announced an extension of its multi-year partnership with Pfizer to use CytoReason’s artificial intelligence […]
European Commission Approves Roche’s Vabysmo, the First Bispecific Antibody for the Eye, for Two Leading Causes of Vision Loss
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) approved Vabysmo® (faricimab) […]
Breakthrough RNA-based Anti-CancerImmunotherapy Treatments Being Developed by Global Consortium Led by the Hadassah Cancer Research Institute
The Hadassah Cancer Research Institute (HCRI) at the Hadassah University Medical Center in Jerusalem, announced today […]
Advanced NanoTherapies' SirPlux Duo Drug-Coated Balloon Receives FDA Breakthrough Designation for Small Vessel Coronary Artery Disease
Advanced NanoTherapies, Inc., a privately-held medical device company committed to solving vascular disease’s most significant […]
ViroCell Announces the Appointment of Susan B. Nichols as CBO
ViroCell, an innovation-driven Contract Development and Manufacturing Organization (“CDMO”), is addressing the global viral vector supply […]
Neuron23 and QIAGEN Announce Collaboration to Develop the First Next-Generation Sequencing Companion Diagnostic for Novel Parkinson's Disease Drug
Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined […]
Biolojic Design Appoints Ronald Herbst, Ph.D., as Chief Scientific Officer
Biolojic Design, a pioneer in the use of artificial intelligence (AI) in antibody design, today announced […]
ObvioHealth Introduces ObvioGo, a Next-Generation DCT Platform and Mobile Application Delivering Stronger Evidence
ObvioHealth, a pioneering virtual research organization (VRO), announces the launch of ObvioGo, a next-generation decentralized […]
Novo Nordisk and Microsoft Collaborate to Accelerate Drug Discovery and Development Using Big Data and Artificial Intelligence
Novo Nordisk and Microsoft have entered a new strategic collaboration to combine Microsoft’s computational services, […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more